Aardvark Therapeutics publishes HERO and OLE trial data presentation
AARD•Aardvark Therapeutics published HERO and OLE data on ARD-101 for Prader-Willi syndrome. HERO enrolled 67 participants before dosing stopped February 27, 2026; results were exploratory, and one Grade 4 cardiac event occurred at 800 mg twice daily.
1. Trial data update
HERO showed modest reductions in hyperphagia scores versus placebo, but early termination left the results exploratory. Former placebo participants had roughly six points of additional improvement on ARD-101 in the extension, while symptoms rebounded after treatment withdrawal. One Grade 4 cardiac event occurred at 800 mg twice daily in a participant taking pitolisant; HERO recorded no additional cardiac events.
